Beam Therapeutics Inc. (BEAM): Total Liabilities
$242.82M
As of 2025-12-31
$318.91M
As of 2026-06-30
-26.4%
3-year compound annual growth
+3.3%
5-year compound annual growth
| Period ended | Total Liabilities | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | $242.82M | -34.4% | 2026-02-24, Balance as of period end |
| 2024-12-31 | $370.28M | -22.6% | 2026-02-24, Balance as of period end |
| 2023-12-31 | $478.38M | -21.3% | 2025-02-25, Balance as of period end |
| 2022-12-31 | $608.24M | -6.1% | 2024-02-27, Balance as of period end |
| 2021-12-31 | $647.72M | +214.2% | 2023-02-28, Balance as of period end |
| 2020-12-31 | $206.12M | +273.7% | 2022-02-28, Balance as of period end |
| 2019-12-31 | $55.15M | n/a | 2021-03-15, Balance as of period end |
Total Liabilities at similar companies
| Company | Year ended | Total Liabilities | Change YoY |
|---|---|---|---|
| Beam Therapeutics Inc. (BEAM) | 2025-12-31 | $242.82M | -34.4% |
| Monte Rosa Therapeutics, Inc. (GLUE) | 2025-12-31 | $215.60M | -0.1% |
| Atara Biotherapeutics, Inc. (ATRA) | 2025-12-31 | $58.74M | -71.5% |
| Ginkgo Bioworks Holdings, Inc. (DNA) | 2025-12-31 | $611.11M | -7.6% |
| REGENXBIO Inc. (RGNX) | 2025-12-31 | $350.30M | +69.8% |
| ImmunityBio, Inc. (IBRX) | 2025-12-31 | $1.00B | +15.0% |
| Adaptimmune Therapeutics PLC (ADAPY) | 2024-12-31 | $234.11M | -3.7% |
| Century Therapeutics, Inc. (IPSC) | 2025-12-31 | $64.77M | -66.2% |
| Sutro Biopharma, Inc. (STRO) | 2025-12-31 | $306.28M | -10.6% |
Compare BEAM, GLUE, ATRA, DNA side by side · Screen every company in Biological Products, (No Diagnostic Substances) ↗